Mar 14, 2023 / 02:00PM GMT
Jeff Jones - Oppenheimer & Co. - Analyst
Good morning, and welcome to day two of Oppenheimer's 33rd Annual Healthcare Conference. I'm Jeff Jones, senior analyst here on the biotechnology team, and I wanted to welcome Jim Caruso, CEO of Cellectar Biosciences.
Jim, I will hand it off to you. Why don't you take this away?
Jim Caruso - Cellectar Biosciences, Inc. - President, CEO, & Director
All right. Terrific, Jeff, thank you very much. And thank you once again for the opportunity to participate in your conference, always appreciate it.
As you may or may not know, the obligatory forward-looking statement is always present in any presentation. Cellectar Biosciences, for those of you that are unfamiliar with the story, has really focused on the research and development of oncology therapeutics, both rare pediatric as well as adult malignancies.
The foundation of our focus is our phospholipid ether or PLE delivery platform. And we have demonstrated the capacity to deliver a wide variety of classes of oncology therapeutics
Cellectar Biosciences Inc at Oppenheimer Healthcare Conference (Virtual) Transcript
Mar 14, 2023
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers